Key facts: Novartis Q2 approvals/pipeline; generics dent; Entresto -50%
Novartis Q2 2026: approvals for Rhapsido (EU, Japan) and Itvisma (EU); Kisqali six‑year follow‑up and FDA pediatric exclusivity; Del‑zota BLA submitted; Del‑brax positive Phase I/I